Acquired Company

TransCode Therapeutics, Inc. acquired Polynoma LLC on October 8, 2025, with CK Life Sciences Int’l., (Holdings) Inc. providing a $25 million financing as part of the transaction.

TransCode Therapeutics Inc. (RNAZ), based in Boston, is a pioneering biopharmaceutical company dedicated to revolutionizing cancer treatment through innovative therapies targeting metastatic diseases. Utilizing its proprietary RNA-based technologies, the firm aims to improve the efficacy of existing cancer therapies while tackling significant unmet needs within the oncology sector. With a strong emphasis on transforming cancer care, TransCode is strategically positioned to become a key player in the biopharmaceutical industry, presenting an appealing investment opportunity for institutional stakeholders interested in the forefront of cancer therapeutics. Show more

Location: 6 LIBERTY SQUARE, BOSTON, MA, UNITED STATES, 02109, Boston, MA, 02109, USA | Website: https://www.transcodetherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

8.702M

52 Wk Range

$6.08 - $399.00

Previous Close

$9.49

Open

$9.50

Volume

6,712

Day Range

$9.21 - $9.96

Enterprise Value

3.835M

Cash

2.836B

Avg Qtr Burn

-4.083M

Insider Ownership

9.22%

Institutional Own.

7.15%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TTX-MC138 Details Cancer, Solid tumor/s	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.